Xencor Aktie

10,20 EUR +0,55 EUR +5,70 %

28.03.2025

FSE

11,23 USD -0,28 USD -2,43 %

nachbörslich28.03.2025

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.730,85 Mio. EUR

Div. Rendite0,00%

WKNA1W96L

ISINUS98401F1057

SymbolXNCR

Xencor Aktien News

Sortieren:Datum Meistgelesen

27.02.24BusinesswireXencor Reports Fourth Quarter and Full Year 2023 Financial Results

20.02.24BusinesswireXencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update

03.01.24BusinesswireXencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference

02.01.24BusinesswireDane Leone Joins Xencor as Senior Vice President, Corporate Strategy

21.11.23BusinesswireXencor to Present at the Piper Sandler 35th Annual Healthcare Conference

07.11.23BusinesswireXencor Sells Portion of Royalties and Milestones from Ultomiris® and Monjuvi® to OMERS Life Sciences for $215 Million

07.11.23BusinesswireXencor Reports Third Quarter 2023 Financial Results

03.11.23BusinesswireXencor Presents Preclinical Data from Multiple XmAb® Research Programs at the SITC Annual Meeting

31.10.23BusinesswireXencor to Host Third Quarter 2023 Financial Results Webcast and Conference Call on November 7, 2023

26.10.23BusinesswireXencor Announces Planned Retirement of Chief Financial Officer John Kuch

27.09.23BusinesswireXencor to Present Multiple Posters at the SITC Annual Meeting

19.09.23BusinesswireXencor Appoints Barbara J. Klencke, M.D., to Board of Directors

03.08.23BusinesswireXencor Reports Second Quarter 2023 Financial Results

27.07.23BusinesswireXencor to Host Second Quarter 2023 Financial Results Webcast and Conference Call on August 3, 2023

31.05.23BusinesswireXencor Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress

08.05.23BusinesswireXencor Reports First Quarter 2023 Financial Results

01.05.23BusinesswireXencor to Host First Quarter 2023 Financial Results Webcast and Conference Call on May 8, 2023

26.04.23BusinesswireXencor Appoints Nancy Valente, M.D., as Chief Development Officer

17.04.23BusinesswireXencor Highlights CD28 Bispecific Antibody Platform at AACR Annual Meeting 2023

14.03.23BusinesswireXencor to Present Preclinical Data from Novel XmAb® CD28 Bispecific Antibody Programs at the American Association for Cancer Research Annual Meeting 2023

23.02.23BusinesswireXencor Reports Fourth Quarter and Full Year 2022 Financial Results

16.02.23BusinesswireXencor to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023

07.02.23BusinesswireXencor to Present at the SVB Securities Global Biopharma Conference

09.01.23BusinesswireXencor Highlights 2023 Corporate Priorities and Provides Portfolio Updates

05.01.23PR NewswireCaris Life Sciences and Xencor Expand Target Discovery Collaboration for Novel XmAb® Antibody Drug Candidates

04.01.23BusinesswireXencor to Present at the 41st Annual J.P. Morgan Healthcare Conference

12.12.22BusinesswireXencor Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma at the American Society of Hematology Annual Meeting

10.11.22BusinesswireXencor Presents Early Clinical Data from Combination Study of Vudalimab and New Data from Multiple Preclinical-stage XmAb® Programs at the SITC Annual Meeting

07.11.22BusinesswireXencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study

07.11.22BusinesswireXencor Reports Third Quarter 2022 Financial Results

03.11.22BusinesswireXencor to Present New Clinical Data from the Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin’s Lymphoma at the American Society of Hematology Annual Meeting

05.10.22BusinesswireXencor to Present Seven Posters on Multiple Clinical Trials and Research-stage Programs at the SITC Annual Meeting

09.09.22BusinesswireXencor Appoints Nancy Valente, M.D., to Board of Directors

03.08.22BusinesswireXencor Reports Second Quarter 2022 Financial Results

02.08.22PR NewswireCaris Life Sciences and Xencor Enter Target Discovery Collaboration and License Agreement for Novel XmAb® Bispecific Antibodies

27.07.22BusinesswireXencor to Host Second Quarter 2022 Financial Results Webcast and Conference Call on August 3, 2022

26.05.22BusinesswireXencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors

05.05.22BusinesswireXencor Reports First Quarter 2022 Financial Results

28.04.22BusinesswireXencor to Host First Quarter 2022 Financial Results Webcast and Conference Call on May 5, 2022

08.04.22BusinesswireXencor Presents Data from Multiple Preclinical XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022

Xencor News

Xencor News: auf dieser Seite finden Sie alle Xencor News und Nachrichten zur Xencor Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Xencor News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Xencor News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.